Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Summit Therapeutics Inc (NASDAQ: SMMT) closed at $17.49 in the last session, down -4.01% from day before closing price of $18.22. In other words, the price has decreased by -$4.01 from its previous closing price. On the day, 3.41 million shares were traded. SMMT stock price reached its highest trading level at $18.12 during the session, while it also had its lowest trading level at $17.37.
Ratios:
We take a closer look at SMMT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Underweight rating and assigned the stock a target price of $13.
On September 04, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $40.
On August 19, 2025, Piper Sandler started tracking the stock assigning a Neutral rating and target price of $21.Piper Sandler initiated its Neutral rating on August 19, 2025, with a $21 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 21 ’25 when Xia Yu bought 533,617 shares for $18.74 per share. The transaction valued at 9,999,983 led to the insider holds 32,057,147 shares of the business.
DUGGAN ROBERT W bought 26,680 shares of SMMT for $499,983 on Oct 21 ’25. The Co-Chief Executive Officer now owns 76,680 shares after completing the transaction at $18.74 per share. On Oct 21 ’25, another insider, Zanganeh Mahkam, who serves as the Co-Chief Executive Officer of the company, bought 26,680 shares for $18.74 each. As a result, the insider paid 499,983 and bolstered with 76,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 13020300288 and an Enterprise Value of 12787174400.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.53, which has changed by -0.12781233 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $15.55. The 50-Day Moving Average of the stock is -15.66%, while the 200-Day Moving Average is calculated to be -21.95%.
Shares Statistics:
According to the various share statistics, SMMT traded on average about 4.08M shares per day over the past 3-months and 3438300 shares per day over the past 10 days. A total of 744.44M shares are outstanding, with a floating share count of 96.87M. Insiders hold about 86.96% of the company’s shares, while institutions hold 13.35% stake in the company. Shares short for SMMT as of 1760486400 were 32272331 with a Short Ratio of 7.92, compared to 1757894400 on 32214253. Therefore, it implies a Short% of Shares Outstanding of 32272331 and a Short% of Float of 27.250000000000004.
Earnings Estimates
Investors are keenly observing as 11.0 analysts analyze and rate. The current performance of Summit Therapeutics Inc (SMMT) in the stock market.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.08 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.1 and -$1.11 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.73, with 10.0 analysts recommending between -$0.34 and -$1.16.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $1.81M in the next fiscal year. The high estimate is $43.49M and the low estimate is -$62.12M.
